Hapbee Technologies Inc (TSX-V:HAPB, OTCQB:HAPBF) has noted that licensor EMulate Therapeutics has published positive pre-clinical data evaluating the use of its light-weight wearable device that uses proprietary WAV files to deliver specific low to ultra-low radio frequency energy (ulRFE) in validated murine models of pain.
The results showed a statistically significant reduction in visceral, neuropathic, and inflammatory pain in the models, the data of which was published in Electromagnetic Biology and Medicine, which can be accessed here.
"We are thrilled to have the results of our latest study published and are encouraged by the positive results,” said Chris Rivera, CEO of EMulate Therapeutics in a statement.
“The information we obtained from this study will inform the design of our future pre-clinical studies and will enable our clinical studies as we continue to explore the untapped potential of our ulRFE technology in the reduction of pain and other disease indications," he added.
READ: Hapbee Technologies uploads new peak performance routines by sports agent and entrepreneur David Meltzer
The use of magnetic fields to affect biological processes in living systems has been well studied for the past several decades. Employing electromagnetic fields like ulRFE to bring about therapeutic results, however, is a more recent development, Hapbee said.
Successful pain reduction from the application of ulRFE has the potential to address common issues with current pharmacological standard of care, the most salient of which is the potential for ulRFE to provide a constant effect to the exposed region, to overcome enzymatic, blood-brain and other barriers to the delivery of drugs to affected parts of the biological system, as well as the effects of delivery, systemic dilution and clearance that are experienced with traditionally administered drugs, it added.
"We are encouraged by the results of this study that show our radio frequency energy WAV files consistently and specifically produced statistically significant effects in the pain models tested, in some cases to a greater effect than the reference drugs used to validate each model," said EMulate's principal scientist Xavier Figueroa, Ph.D.
"These results suggest that the magnetic fields produced by our WAV files, and particularly those with frequencies below 10 kHz, can provide an efficacious reduction in pain sensation in these pain studies," he added.
EMulate Therapeutics is a clinical-stage company utilizing its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE) to provide safe and effective therapeutic benefits specifically targeted at patients' underlying conditions.
The company has generated encouraging human data from patients afflicted with glioblastoma and diffuse midline glioma and is preparing for pivotal Phase 3 studies in each indication. It has also generated encouraging pre-clinical studies in pain management and mental health models and is preparing for initial human clinical trials in each area.
In addition, positive data have been generated independently in animal health (positive cancer results in over 20 different solid tumor types in canines (pets)), as well as in bio-agriculture models. EMulate is the licensor of this proprietary technology to Hapbee.
Emulate’s non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered, portable investigational medical device uses low to ultra-low level (DC-22kHz) frequencies to deliver specific electromagnetic signals to reduce pain sensations. The system emits a low power magnetic field (<100 mG) that can be applied locally or globally, dependent on the type of therapeutic effect sought. The signals are stored as WAV files on the device and emitted via a cable to the attached antenna unit.
Hapbee is a commercial-stage consumer wellness-wearable technology company spun out from EMulate in 2019, and is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.
Contact the author at jon.hopkins@proactiveinvestors.com